N/A
N=10
Ablation at Virtual-hEart pRedicted Targets for VT
Ventricular Tachycardia · Ischemic Cardiomyopathy
Bottom Line
View on ClinicalTrials.gov: NCT03536052 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Number of Participants With Ventricular Tachycardia Inducibility — 6 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Virtual Heart Guided Ablation (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Johns Hopkins University
- Primary completion
- Dec 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Ventricular Tachycardia Inducibility |
6 | — |
| SECONDARY Freedom From Ventricular Tachycardia |
2 | — |
Summary
The goal of this study is to test the efficacy of the new imaging/simulation ("virtual heart") approach for determining the optimal ablation sites in patients with VT, which render post-infarction VT non-inducible. The study will test both the acute outcome of the ablation procedure, and the effect the use of the predicted targets has upon procedure time.
Eligibility Criteria
Inclusion Criteria
- Eligible patients must be at least 18 years old at the time of enrollment.
- A Pre-Op cardiac MRI including late gadolinium enhancement (LGE) must be performed prior to ablation. As Johns Hopkins University (JHU) performs MRIs with implantable cardioverter defibrillator (ICD) or pacemaker implanted, patients with these devices may be enrolled.
- Eligible patients must suffer from VT, thought to be secondary to structural heart disease (scarring).
- Eligible patients must be determined to be suitable candidates for ablation to treat VT by their cardiologist and/or electrophysiologists regardless of this protocol.
Exclusion Criteria
- Patients with Glomerular Filtration Rate (GFR) < 30 mL/min should not be enrolled in the study due to the use of intravenous gadolinium as an MRI contrast agent
- If a pre-procedure MRI cannot or likely will not be performed for any reason (such as claustrophobia), the patient must be excluded.
- Pregnant women may not participate in the study because gadolinium MRI contrast is contraindicated in these patients.
- Any subject that, during the course of the pre-procedure imaging, is discovered to have VT not related to scarring, he/she must be de-enrolled from the study.
Data sourced from ClinicalTrials.gov (NCT03536052). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.